<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83943">
  <stage>Registered</stage>
  <submitdate>20/05/2009</submitdate>
  <approvaldate>11/06/2009</approvaldate>
  <actrnumber>ACTRN12609000440224</actrnumber>
  <trial_identification>
    <studytitle>Clopidogrel vs Aspirin in Congestive Heart Failure (CACHE)</studytitle>
    <scientifictitle>A multi-centre, randomised clinical trial examining the effect of Clopidogrel versus Aspirin in addition to optimal medical therapy for heart failure on subsequent heart failure hospitalisation and mortality in patients with class III-IV congestive heart failure.</scientifictitle>
    <utrn />
    <trialacronym>CACHE</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Clopidogrel 75mg oral tablet taken once per day for an average of 3 years (maximum 5 years).</interventions>
    <comparator>Aspirin 100mg oral tablet taken once per day for an average of 3 years (maximum 5 years).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The first occurrence of any heart failure hospitalisation or death from any cause</outcome>
      <timepoint>Average of 3 years follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>Average of 3 years follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause hospitalisation</outcome>
      <timepoint>Average of 3 years follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalisation for bleeding</outcome>
      <timepoint>Average of 3 years follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalisation for heart failure</outcome>
      <timepoint>Average of 3 years follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Men or women age &gt;18 years
2. Symptomatic heart failure
3. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) of &gt;600pg/mL 
OR NT-proBNP &gt;400pg/mLa + Heart Failure (HF) hospitalisation within last 12 months
4. Treatment with an angiotensin converting enzyme (ACE) inhibitor (unless not tolerated) and ongoing treatment with a diuretic 
5. Provision of written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Contraindication to aspirin or clopidogrel
2. Indication for chronic anti-coagulation
3. Heart failure due to a reversible cause or  hypertrophic or infiltrative cardiomyopathy
4. Unstable heart failure or treatment regimen
5. Life-limiting systemic illness
6. Severe chronic obstructive pulmonary disease (COPD) (as evidenced by history of mechanical ventilation, need for home oxygen, or treatment with oral corticosteroids) for more than 3 continuous days within 12 months
7. Conditions that might interfere with protocol compliance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients who fulfill the eligibilty criteria and give their written informed consent to take part will be randomised centrally using a stratified minimisation method. Patients will be allocated open label aspirin or clopidogrel.
Randomisation will be performed at the National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC)</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown
NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>awaiting confirmation of funding</fundingname>
      <fundingaddress>awaiting confirmation of funding</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The underlying hypothesis for CACHE is that patients with congestive heart failure who receive clopidogrel will experience fewer heart failure outcomes when compared to patients receiving aspirin.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>This study was withdrawn as funding was not received</publicnotes>
    <ethicscommitee>
      <ethicname>St Vincent's and Mater HREC (EC00140)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/07/2009</ethicapprovaldate>
      <hrec>HREC/09/SVH/65</hrec>
      <ethicsubmitdate>21/05/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>CACHE Coordinator</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown
NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>CACHE@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>CACHE Coordinator</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown
NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>CACHE@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>CACHE Coordinator</name>
      <address>NHMRC Clinical Trials Centre
University of Sydney
Locked Bag 77
Camperdown
NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax />
      <email>CACHE@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Christopher Hayward</name>
      <address>Suite 809, Level 8,
St Vincent's Clinic
438 Victoria St,
Darlinghurst 2010
</address>
      <phone>+61 2 8382 6880</phone>
      <fax />
      <email>cshayward@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>